April 24, 2007 — Abiomed Inc. has announced completion of the enrollment of 20 patients in its pilot clinical trial of the Impella 2.5 Circulatory Support System. The trial will be completed after the company has concluded all necessary post-enrollment patient monitoring.
The pilot trial will study outcomes for patients undergoing high-risk angioplasty procedures at the trial sites of William Beaumont Hospital, Brigham and Women's Hospital, Massachusetts General Hospital, Texas Heart Institute, Cedars-Sinai Medical Center, Scripps Clinic and the Academic Medical Center in Amsterdam.
Abiomed will host a conference call and Webcast on April 27, 1 p.m. ET, to discuss data on its Impella 2.5 that was presented by Dr. Jose P. Henriques from the Academic Medical Center in Amsterdam, at the American College of Cardiology's (ACC) 56th Annual Scientific Sessions. That study, titled "Preliminary Experience of the MACH 2 Trial: Safety and Feasibility of Left Ventricular Support with the Impella Recover LP2.5 Device in Patients with Acute ST-Segment Elevation Myocardial Infarction," found that the Impella 2.5 improved cardiac function for pre-shock acute myocardial infarction (AMI or heart attack) as compared to conventional care including intra-aortic balloon pump (IABP) therapy.
To listen to April 27 conference call live, tune into the Webcast via http://investor.abiomed.com or dial 800-798-2801; the international number is 617-614-6205. The access code is 18688274. A replay of this conference call will be available beginning at 3 p.m. ET April 27 through May 4, 2007. The replay phone number is 888-286-8010; the international number is 617-801-6888. The replay access code is 95044880.
For more information visit www.abiomed.com.
June 19, 2024 
